bioRxiv Science⌕ Search

Biology subjects

Beeman, S. C.

Publications and source records attributed to Beeman, S. C..

2 recordsLinked to original sources

Towards MR-based interrogation of the hypoxia-driven insulin resistance mechanism: Adipocytes size estimation.

Obesity is a major risk factor for type 2 diabetes, yet not all individuals with obesity develop metabolic disease, underscoring the need for mechanistic biomarkers. Adipocyte hypertrophy is a hypothesized driver of insulin resistance, but current methods for quantifying adipocyte size are invasive. Here, we propose and validate a non-invasive MRI approach based on "short diffusion time" diffusion-weighted MR spectroscopy to estimate adipocyte size in vivo. Monte Carlo simulations confirmed the methods accuracy across a physiologic range of adipocyte sizes (20 - 150 m) and signal-to-noise ratios (SNR > 40). We applied this technique to the epididymal white adipose tissue (eWAT) of rats using in vivo 4.7T and ex vivo 11.7T MRI. Adipocyte sizes derived from diffusion MRI showed good agreement with histology, with minor systematic underestimation corrected by empirical factors. This approach does not require complex modeling or high diffusion weighting, increasing its translatability to the laboratory and clinical settings. Diffusion MRI may serve as a non-invasive "virtual biopsy" to monitor adipocyte morphology and improve understanding of obesity-related metabolic dysfunction.

bioengineering↗

2H MRI-based quantification of leucine uptake in glioblastoma multiforme

Glioblastoma (GBM) brain tumors are among the most lethal of all human cancers, with a median survival time of [~]15 months. Treatment planning requires radiologic demarcation of tumor boundaries with contrast-enhanced magnetic resonance imaging (CE MRI); however, significant tumor burden extends beyond the contrast-enhancing margins of the tumor. GBM tumors have an increased expression of amino acid (AA) transporters, including the Alanine, Serine, Cysteine Transporter 2 (ASCT2) and the L-Type Amino Acid Transporter 1 (LAT1). This upregulation has been leveraged in positron emission tomography (PET) studies to detect tumor burden beyond the contrast-enhancing margins identified by standard-of-care CE MRI. Here we leverage recent approaches in deuterium metabolic magnetic resonance with this known upregulation of AA transporters in GBM to demonstrate that 2H MR can detect glioma based on enhanced branched- chain amino acid (BCAA) uptake. To the best of our knowledge, these data represent the first non- invasive quantification of AA concentrations in brain tumor and raises the potential to (i) detect tumor burden beyond contrast-enhancing margins and (ii) quantify AA metabolism using 2H MR spectroscopy.

cancer biology↗